Cargando…

Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization

The derived neutrophil to lymphocyte ratio (dNLR) has been proposed as an easily determinable prognostic factor for cancer patients, but the prognostic significance of the dNLR in hepatocellular carcinoma (HCC) has not been investigated. The present study aimed to validate the prognostic power of th...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHOU, DONGSHENG, LIANG, JIANZHONG, XU, LI, HE, FENGYING, ZHOU, ZHONGGUO, ZHANG, YAOJUN, CHEN, MINSHAN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840749/
https://www.ncbi.nlm.nih.gov/pubmed/27123051
http://dx.doi.org/10.3892/ol.2016.4359
_version_ 1782428303023407104
author ZHOU, DONGSHENG
LIANG, JIANZHONG
XU, LI
HE, FENGYING
ZHOU, ZHONGGUO
ZHANG, YAOJUN
CHEN, MINSHAN
author_facet ZHOU, DONGSHENG
LIANG, JIANZHONG
XU, LI
HE, FENGYING
ZHOU, ZHONGGUO
ZHANG, YAOJUN
CHEN, MINSHAN
author_sort ZHOU, DONGSHENG
collection PubMed
description The derived neutrophil to lymphocyte ratio (dNLR) has been proposed as an easily determinable prognostic factor for cancer patients, but the prognostic significance of the dNLR in hepatocellular carcinoma (HCC) has not been investigated. The present study aimed to validate the prognostic power of the NLR and dNLR in HCC patients undergoing transarterial chemoembolization (TACE). The data of 279 consecutive patients who underwent TACE for unresectable HBV-associated HCC between September 2009 and November 2011 at the Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center (Guangzhou, China) were retrieved from a prospective database. The cut-off values for the NLR and dNLR were determined by receiver operating characteristic (ROC) analysis. The association between the NLR and dNLR and the clinicopathological characteristics and overall survival (OS) rates and times of patients was analyzed. The area under the curve (AUC) was calculated to evaluate the discriminatory ability of the NLR and dNLR. The median follow-up period was 446 days, the 1, 2 and 3-year OS rates were 38.8, 18.5 and 11.1% respectively, and the median OS time was 264 days. The cut-off values were determined as 2.6 and 1.8 for the NLR and dNLR, respectively. The NLR and dNLR were each associated with patient age, presence of vascular invasion, tumor size, AST level and ALP level. Multivariate analysis showed that the NLR, dNLR, ALT level and AFP level were independent prognostic factors for OS. An elevated NLR or dNLR was associated with a poor prognosis (P=0.001 and P=0.002, respectively). The prognostic power of NLR [AUC=0.539; 95% confidence interval (CI), 0.423–0.656] and dNLR (AUC=0.522; 95% CI, 0.406–0.638) was similar. Elevated dNLR predicted poor prognosis for patients with HBV-associated HCC undergoing TACE, with similar prognostic power to NLR. The dNLR may be used as an alternative to the NLR, as it is easily available and inexpensive.
format Online
Article
Text
id pubmed-4840749
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-48407492016-04-27 Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization ZHOU, DONGSHENG LIANG, JIANZHONG XU, LI HE, FENGYING ZHOU, ZHONGGUO ZHANG, YAOJUN CHEN, MINSHAN Oncol Lett Articles The derived neutrophil to lymphocyte ratio (dNLR) has been proposed as an easily determinable prognostic factor for cancer patients, but the prognostic significance of the dNLR in hepatocellular carcinoma (HCC) has not been investigated. The present study aimed to validate the prognostic power of the NLR and dNLR in HCC patients undergoing transarterial chemoembolization (TACE). The data of 279 consecutive patients who underwent TACE for unresectable HBV-associated HCC between September 2009 and November 2011 at the Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center (Guangzhou, China) were retrieved from a prospective database. The cut-off values for the NLR and dNLR were determined by receiver operating characteristic (ROC) analysis. The association between the NLR and dNLR and the clinicopathological characteristics and overall survival (OS) rates and times of patients was analyzed. The area under the curve (AUC) was calculated to evaluate the discriminatory ability of the NLR and dNLR. The median follow-up period was 446 days, the 1, 2 and 3-year OS rates were 38.8, 18.5 and 11.1% respectively, and the median OS time was 264 days. The cut-off values were determined as 2.6 and 1.8 for the NLR and dNLR, respectively. The NLR and dNLR were each associated with patient age, presence of vascular invasion, tumor size, AST level and ALP level. Multivariate analysis showed that the NLR, dNLR, ALT level and AFP level were independent prognostic factors for OS. An elevated NLR or dNLR was associated with a poor prognosis (P=0.001 and P=0.002, respectively). The prognostic power of NLR [AUC=0.539; 95% confidence interval (CI), 0.423–0.656] and dNLR (AUC=0.522; 95% CI, 0.406–0.638) was similar. Elevated dNLR predicted poor prognosis for patients with HBV-associated HCC undergoing TACE, with similar prognostic power to NLR. The dNLR may be used as an alternative to the NLR, as it is easily available and inexpensive. D.A. Spandidos 2016-05 2016-03-21 /pmc/articles/PMC4840749/ /pubmed/27123051 http://dx.doi.org/10.3892/ol.2016.4359 Text en Copyright: © Zhou et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
ZHOU, DONGSHENG
LIANG, JIANZHONG
XU, LI
HE, FENGYING
ZHOU, ZHONGGUO
ZHANG, YAOJUN
CHEN, MINSHAN
Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization
title Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization
title_full Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization
title_fullStr Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization
title_full_unstemmed Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization
title_short Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization
title_sort derived neutrophil to lymphocyte ratio predicts prognosis for patients with hbv-associated hepatocellular carcinoma following transarterial chemoembolization
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840749/
https://www.ncbi.nlm.nih.gov/pubmed/27123051
http://dx.doi.org/10.3892/ol.2016.4359
work_keys_str_mv AT zhoudongsheng derivedneutrophiltolymphocyteratiopredictsprognosisforpatientswithhbvassociatedhepatocellularcarcinomafollowingtransarterialchemoembolization
AT liangjianzhong derivedneutrophiltolymphocyteratiopredictsprognosisforpatientswithhbvassociatedhepatocellularcarcinomafollowingtransarterialchemoembolization
AT xuli derivedneutrophiltolymphocyteratiopredictsprognosisforpatientswithhbvassociatedhepatocellularcarcinomafollowingtransarterialchemoembolization
AT hefengying derivedneutrophiltolymphocyteratiopredictsprognosisforpatientswithhbvassociatedhepatocellularcarcinomafollowingtransarterialchemoembolization
AT zhouzhongguo derivedneutrophiltolymphocyteratiopredictsprognosisforpatientswithhbvassociatedhepatocellularcarcinomafollowingtransarterialchemoembolization
AT zhangyaojun derivedneutrophiltolymphocyteratiopredictsprognosisforpatientswithhbvassociatedhepatocellularcarcinomafollowingtransarterialchemoembolization
AT chenminshan derivedneutrophiltolymphocyteratiopredictsprognosisforpatientswithhbvassociatedhepatocellularcarcinomafollowingtransarterialchemoembolization